Letters in Drug Design & Discovery is an esteemed journal dedicated to advancing the fields of Drug Discovery and Molecular Medicine. Published by Bentham Science Publishers, this journal offers a platform for the dissemination of innovative research and advanced methodologies, enhancing collaboration among researchers and professionals in pharmaceutical sciences. Despite its current Q4 ranking in Drug Discovery and Molecular Medicine and Q3 in Pharmaceutical Science for 2023, the journal is committed to improving its presence in the academic community by providing quality, peer-reviewed publications that cover various aspects of drug design and discovery, including novel therapeutic approaches and methodologies. With a focus on both foundational and cutting-edge research from around the globe, Letters in Drug Design & Discovery is pivotal for those seeking to stay abreast of developments in drug development and molecular research. Researchers are encouraged to submit their work, engage with the burgeoning field, and contribute to the ongoing dialogue driven by this journal, which spans the years from 2005 to 2024. While the journal does not currently offer open access, its contributions remain accessible to a wide range of academic and professional audiences.

Advances in Pharmacological and Pharmaceutical Sciences is a premier open-access journal published by Hindawi Ltd. based in the United Kingdom. Established in 2020, the journal swiftly garnered attention for its commitment to disseminating high-quality research in the realms of pharmacology, toxicology, and pharmaceutical sciences. It holds a commendable impact with notable quartile rankings, including Q2 in both Organic Chemistry and Pharmacology, indicating its importance within these disciplines. By embracing an open-access model, the journal ensures that research findings are widely available, promoting increased visibility and collaboration among researchers, professionals, and students globally. With an ongoing convergence of insights projected through 2024, Advances in Pharmacological and Pharmaceutical Sciences aims to address critical issues and advancements in drug development and therapeutic practices, making it an invaluable resource for those at the forefront of scientific inquiry in pharmacology and related fields.

CURRENT PHARMACEUTICAL BIOTECHNOLOGY is a prestigious academic journal dedicated to advancing the field of pharmaceutical biotechnology by publishing high-quality research articles, reviews, and innovatory methodologies. Published by Bentham Science Publishers Ltd, this journal has established a strong reputation in its field, reflected in its 2023 Scopus rankings: it holds an impressive Q2 classification in Pharmaceutical Science and Q3 in Biotechnology, indicating its significant impact within these disciplines. With an ISSN of 1389-2010 and an E-ISSN of 1873-4316, CURRENT PHARMACEUTICAL BIOTECHNOLOGY provides a reliable platform for disseminating valuable research findings and fostering collaboration among researchers, professionals, and students alike. The journal covers a wide array of topics, from drug development and delivery systems to innovative biotechnological techniques, thus serving as an essential resource for anyone interested in the cross-section of pharmaceutical science and biotechnology. Researchers can access a diverse range of articles that explore both theoretical frameworks and practical applications, reflecting the ongoing evolution and challenges in this dynamic field.

Acta Pharmaceutica Sinica B is a prestigious open access journal that has been setting the standard in the field of pharmacology, toxicology, and pharmaceutics since its establishment in 2011. Published by the Institute of Materia Medica, Chinese Academy of Medical Sciences, the journal serves as a vital platform for researchers, professionals, and students seeking to disseminate innovative findings in drug development, pharmaceutical sciences, and therapeutic applications. With an impressive impact factor reflecting its high academic quality, Acta Pharmaceutica Sinica B has achieved Q1 status in the category of Pharmacology, Toxicology and Pharmaceutics as of 2023, ranking #1 out of 80 journals in General Pharmacology. This journal not only focuses on the latest advancements in drug research and formulation but also emphasizes interdisciplinary approaches, fostering collaborations that span various scientific domains. The accessible nature of the journal, combined with its rigorous peer-review process, ensures that crucial insights and breakthroughs reach a global audience swiftly and effectively. For those looking to stay at the forefront of pharmaceutical research, Acta Pharmaceutica Sinica B is an indispensable resource.

Drug Target Insights is a prestigious peer-reviewed journal published by ABOUTSCIENCE SRL, catering to the dynamic field of pharmacology and medicinal biochemistry. With an Open Access policy since 2006, the journal aims to promote the dissemination of cutting-edge research and innovations that target drug discovery and therapeutic developments. Based in Milan, Italy, it boasts a notable impact within its research community, achieving a Q3 classification in the categories of Clinical Biochemistry and Medical Pharmacology in 2023, alongside a robust performance in the Q2 category for Pharmacology, Toxicology, and Pharmaceutics. The journal serves as a vital platform for researchers, professionals, and students seeking to advance their understanding of drug delivery systems, therapeutic targets, and pharmacodynamics. With a commitment to enhancing global access to crucial research findings, Drug Target Insights stands out as an essential resource for those engaged in the ever-evolving landscape of pharmaceutical sciences.

BIOLOGICAL & PHARMACEUTICAL BULLETIN, published by the PHARMACEUTICAL SOC JAPAN, is a prominent peer-reviewed journal that serves the fields of medicine, pharmaceutical science, and pharmacology. With an ISSN of 0918-6158 and an E-ISSN of 1347-5215, this publication has been crucial in disseminating innovative research since its inception in 1993, and it continues to contribute significantly to the body of knowledge as it converges towards 2024. Despite being classified as a non-open access journal, it maintains a respectable Q3 ranking in Medicine (miscellaneous) and Q2 in Pharmaceutical Science, highlighting its critical role in advancing scientific discourse in these areas. With Scopus rankings placing it in the 51st percentile for Pharmaceutical Science and 38th percentile for Pharmacology, BIOLOGICAL & PHARMACEUTICAL BULLETIN is an essential resource for researchers, professionals, and students looking to stay abreast of cutting-edge developments and trends in biomedicine and drug development.

ACTA PHARMACOLOGICA SINICA is a premier journal in the field of pharmacology, published by the esteemed Nature Publishing Group. With a strong history since its inception in 1980, this journal is recognized for its impactful contributions to the fields of medicine and pharmacology, consistently securing a Q1 ranking in multiple relevant categories, including Pharmacology (Medical). Drawing on a robust international readership, it ranks impressively at #8 out of 272 in the specialty of Medical Pharmacology, placing it in the top 97th percentile according to Scopus data. Although currently not an open-access publication, ACTA PHARMACOLOGICA SINICA remains a vital resource for researchers, professionals, and students seeking to advance their understanding of pharmacological sciences. Its commitment to disseminating high-quality research underscores its significance in fostering innovation and exploration in the medical landscape.

PLANTA MEDICA is a premier journal dedicated to advancing the field of medicinal plant research, published by Georg Thieme Verlag KG in Germany. With an ISSN of 0032-0943 and an E-ISSN of 1439-0221, this journal has been a cornerstone of scholarly communication since its inception in 1961. Recognized for its rigorous peer-review process, PLANTA MEDICA holds a notable reputation in the academic landscape, featuring a 2023 Q2 ranking in categories such as Analytical Chemistry and Pharmaceutical Science, along with respectable Q3 rankings in Drug Discovery and Molecular Medicine. The journal focuses on the synthesis, pharmacological, and biochemical assessment of phytochemicals, making it an essential resource for researchers, professionals, and students alike who are engaged in the exploration of complementary and alternative medicine. Although it does not offer open access options, its content is instrumental in identifying new therapeutic agents derived from plants, thereby underscoring its importance in drug discovery and holistic health research.

Current Computer-Aided Drug Design, published by BENTHAM SCIENCE PUBL LTD, is a pivotal journal dedicated to the integration of computer-aided methodologies within the drug design process. With its ISSN 1573-4099 and E-ISSN 1875-6697, this journal serves as a vital resource for researchers, professionals, and students interested in advancing the fields of pharmacology and molecular medicine. Operating under a framework that spans from 2006 to 2024, it aims to foster innovative approaches and discussions surrounding drug design strategies, computational techniques, and the therapeutic potential of novel compounds. Although it currently holds a Q4 rating in Drug Discovery and Molecular Medicine as well as a Q3 in Medicine (miscellaneous) within the 2023 category quartiles, the journal continues to enhance its visibility and relevance in the academic community. Its Scopus rankings reflect its commitment to quality research, positioning it in the context of drug discovery and molecular studies. As the field of drug design evolves, Current Computer-Aided Drug Design remains an essential platform for disseminating cutting-edge findings and facilitating collaboration among specialists aiming for significant advancements in drug development.

The European Journal of Pharmacology, a prestigious publication by Elsevier, serves as a vital resource in the field of pharmacology, offering rich insights into drug development and therapeutic applications. Since its inception in 1967, this journal has evolved to encompass groundbreaking research, including pharmacokinetics, toxicology, and innovative pharmacological methodologies, making it an essential platform for researchers and professionals alike. With an impressive impact factor that places it in the Q1 category of pharmacological journals and a Scopus ranking of #49 out of 313, the journal is recognized in the 84th percentile within its category, solidifying its significance in the academic community. Although the journal is not open access, it continues to attract contributions from leading scientists worldwide, ensuring that cutting-edge findings are disseminated effectively. The European Journal of Pharmacology not only highlights advancements in drug discovery and clinical applications but also promotes interdisciplinary collaboration, ultimately contributing to the progress of healthcare globally.